Cytisinicline Shows Potential for Smoking Cessation in COPD
Cytisinicline increased continuous smoking abstinence versus placebo with statistical significance in both COPD and non-COPD subgroups across the Phase...
New Hope for Neuropathic Corneal Pain: A Urcosimod Trial
In a randomized, double-masked, placebo-controlled Phase 2 proof-of-concept study of 17 patients with neuropathic corneal pain (NCP), 75% of...
New Vitiligo Therapy Shows Unprecedented Response Rates
A 251-patient, multicenter randomized controlled trial in adults with localized non-segmental vitiligo reported that combining a 308 nm excimer...
Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s
Phase 2 data from the ASCEND trial of solengepras signaled potential benefit on functional and non-motor measures in early...
Adverum Finishes Screening for Pivotal ARTEMIS Wet AMD Trial
Screening for Adverum’s first Phase 3 trial of its intravitreal gene therapy for wet AMD will close by September...
C4’s Cemsidomide Data Supports Best-in-Class Myeloma Drug
C4 Therapeutics reported a 50% overall response rate at 100 µg and 40% at 75 µg for cemsidomide plus...
Kensana Health’s $120M Surge Fuels Plant Medicine Future
Kensana Health secured a share subscription facility of up to $120 million with GEM Global Yield, available for 36...
SKYE Presents New Phase 1b Nimacimab Data at EASD Meeting
No serious adverse events, no discontinuations due to adverse events, and no neuropsychiatric safety signals were observed in a...
PDS Biotech Breakthrough Extends Head & Neck Cancer Survival
In a Phase 2 sub-analysis of HPV16-positive first-line recurrent or metastatic head and neck squamous cell carcinoma with low...
NKGen Reveals Hope for Neurodegenerative Disease at China Forum
No new efficacy or safety figures were released, but NKGen Biotech plans to present recent clinical data on its...